Since January 2020 Elsevier has created a COVID-19 resource centre with
free information in English and Mandarin on the novel coronavirus COVID-
  19. The COVID-19 resource centre is hosted on Elsevier Connect, the
             company's public news and information website.


   Elsevier hereby grants permission to make all its COVID-19-related
research that is available on the COVID-19 resource centre - including this
  research content - immediately available in PubMed Central and other
publicly funded repositories, such as the WHO COVID database with rights
for unrestricted research re-use and analyses in any form or by any means
   with acknowledgement of the original source. These permissions are
 granted for free by Elsevier for as long as the COVID-19 resource centre
                             remains active.
                                                               Journal of Affective Disorders 333 (2023) 571–571


                                                                    Contents lists available at ScienceDirect


                                                            Journal of Affective Disorders
                                                            journal homepage: www.elsevier.com/locate/jad


Corrigendum

Corrigendum to “Effects of the COVID-19 pandemic and lockdown in Spain:
Comparison between community controls and patients with a psychiatric
disorder. Preliminary results from the BRIS-MHC STUDY” [J. Affect Disord.
2021 Feb 15; 281:13–23]
B. Solé a, 1, N. Verdolini a, 1, S. Amoretti a, L. Montejo a, A.R. Rosa b, B. Hogg c, C. Garcia-Rizo a,
G. Mezquida a, M. Bernardo a, A. Martinez-Aran a, E. Vieta a, *, C. Torrent a
a
  Bipolar and Depressive Disorders Unit, Hospital Clinic, Institute of Neurosciences, University of Barcelona, IDIBAPS, CIBERSAM, Barcelona, Catalonia, Spain;
Barcelona Clinic Schizophrenia Unit, Hospital Clinic of Barcelona, August Pi I Sunyer Biomedical Research Institute (IDIBAPS), CIBERSAM, Neuroscience Institute,
University of Barcelona, Spain
b
  Laboratory of Molecular Psychiatry, Hospital de Clínicas de Porto Alegre (HCPA), Porto Alegre, RS, Brazil; Department of Pharmacology, Postgraduate Program in
Psychiatry and Behavioral Sciences and Postgraduate Program of Pharmacology and Therapeutics, Universidade Federal do Rio Grande do Sul (UFRGS), Porto Alegre,
RS, Brazil
c
  Centre Fórum Research Unit, Parc de Salut Mar, Barcelona, Spain; Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain; Predoctoral program,
Department of Psychiatry and Forensic Medicine, Universitat Autònoma de Barcelona (UAB), Spain


  The authors regret we did not include the following funding infor­                            through the project “PI20/00344” and co-funded by the European
mation in the Acknowledgments section.                                                          Union.
  This study has been funded by Instituto de Salud Carlos III (ISCIII)                             The authors would like to apologise for any inconvenience caused.


      DOI of original article: https://doi.org/10.1016/j.jad.2020.11.099.
    * Corresponding author.
      E-mail address: evieta@clinic.cat (E. Vieta).
    1
      The first two authors contributed equally to this work.

https://doi.org/10.1016/j.jad.2023.04.087

Available online 28 April 2023
0165-0327/© 2023 Elsevier B.V. All rights reserved.